Revolution Medicines' RMC-4630 shows anti-tumor activity in colorectal cancer; collaborates with AstraZeneca

• Revolution Medicines (NASDAQ:RVMD) reports interim data from its Phase 1b/2 clinical trial (RMC-4630-02) evaluating the combination of RMC-4630 and Genentech's cobimetinib (Cotellic) in adult patients with relapsed/refractory solid tumors that harbor specific genomic RAS pathway mutations at the EORTC-NCI-AACR 32^nd Symposium on Molecular Targets and Cancer Therapeutics.
• Interim results suggest that a dual intermittent dosing strategy exceeds target plasma exposures for each drug based on preclinical models of RAS pathway-driven cancers that project potential clinical activity.
• As of the data cut-off date, tumor volume reduction was observed in three of seven patients who were treated at the highest dose of RMC-4630, including one unconfirmed partial response.
• The adverse event profile was consistent with expected on-pathway effects of both drugs and was tolerable.
• The results of this study will inform company's pending selection of a recommended Phase 2 dose and schedule for the drug combination to be evaluated further.
• Revolution Medicines has also signed an agreement with AstraZeneca (NASDAQ:AZN) to study RMC-4630 in combination with an emerging asset from latter's preclinical efforts targeting KRAS^G12C.
• Under the agreement, AZN will sponsor and conduct this combination study and RVMD will provide clinical supply of RMC-4630.
• https://seekingalpha.com/news/3625551-revolution-medicines-rmcminus-4630-shows-anti-tumor-activity-in-colorectal-cancer